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Abstract
Background Inhaled LPS causes neutrophilic airway inflam-
mation in healthy subjects. We compared the effects of p38
MAPK inhibitors and fluticasone propionate on the LPS
response.
Methods Three randomised, double-blind, placebo-con-
trolled, single dose crossover studies were performed. Active
treatments were the oral p38 MAPK inhibitor PH-797804
30 mg (study 1), PH-797804 30 mg and the inhaled p38
MAPK inhibitor PF-03715455 20 mg (study 2) and inhaled
fluticasone propionate 500 μg (study 3). The primary end-
point was sputum neutrophil percentage.
Results Sputum neutrophil percentage post-LPS challenge
was significantly inhibited (15.1 and 15.3 % reduction) by
PH-797804 compared to placebo in studies 1 and 2 (p=
0.0096 and 0.0001, respectively), and by PF-03715455
(8.0 % reduction, p=0.031); fluticasone propionate had no
effect. PH-797804 significantly inhibited the increase in
inflammatory mediators (IL-6, MCP-1, MIP1β and CC16)
in sputum supernatant, while PF-03715455 had no effect.
PH-797804 and PF-03715455 both inhibited IL-6, MCP-1,
MIP1β, CC16 and CRP levels in plasma, with PH-797804
having greater effects. Fluticasone propionate had no effect
on sputum supernatant or plasma biomarkers.
Conclusions PH-797804 had the greatest impact on neutro-
philic airway inflammation. Oral administration of p38
MAPK inhibitors may optimise pulmonary anti-inflammatory
effects.
Keywords p38MAPK inhibitors . LPS challenge . Induced
sputum
Introduction
Chronic obstructive pulmonary disease (COPD) is
characterised by neutrophilic airway inflammation [1].
Neutrophils secrete pro-inflammatory mediators as well as
proteases that cause tissue destruction [2]. Inhaled corticoste-
roids (ICS) are the most commonly used anti-inflammatory
drug in COPD but have only modest clinical benefits [3] that
are greatest in the subgroup of COPD patients with increased
eosinophil numbers [4]. Novel drugs are needed to target neu-
trophilic airway inflammation in COPD.
The p38 mitogen-activated protein kinase (MAPK) signal-
ling pathway regulates inflammatory gene expression in many
different cell types by the activation of transcription factors
including nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NFκB) and activating transcription factor 2
(ATF2) [5]. p38 MAPK can also contribute to inflammation
by stabilising mRNAs and increasing protein translation [5].
A range of extracellular stimuli activate the p38 MAPK path-
way, including toll-like receptor (TLR) agonists such as the
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TLR4 agonist bacterial lipopolysaccharide (LPS) [5]. The
expression of activated p38 MAPK is increased in the
lungs of COPD patients compared to healthy controls [6,
7], implicating this pathway in the inflammatory process-
es in COPD. p38 MAPK inhibitors demonstrate anti-
inflammatory effects in a range of animal models of air-
way inflammation [8] and also reduce cytokine produc-
tion from COPD alveolar macrophages, lung lymphocytes
and bronchial epithelial cells in vitro [6, 9]. p38 MAPK
inhibitors are currently being evaluated in clinical trials
for the treatment of COPD [10–13].
Historically, orally administered p38 MAPK inhibitors
have often been poorly tolerated, probably due to Boff
target^ effects on other kinases leading to side effects
such as liver toxicity [14]. More recently developed oral
p38 MAPK inhibitors have greater selectivity against the
p38 MAPK α and β i soforms; PH-797804 and
losmapimod have been well tolerated in COPD trials up
to 24-week duration [11–13]. Furthermore, PH-797804
has demonstrated a clinically significant improvement in
pulmonary function [11]. However, there are still con-
cerns about the long-term tolerability of p38 MAPK in-
hibitors, so an alternative strategy is to administer p38
MAPK inhibitors by inhaled delivery in order to minimise
side effects by reducing systemic exposure. However, the
therapeutic effectiveness of inhaled delivery for this class
of drug is unknown.
The inhalation of LPS causes an influx of inflammatory
cells into the airways of healthy subjects, with an increase in
the proportion of neutrophils observed in induced sputum
[15]. This healthy volunteer model is used as a relevant chal-
lenge model to study potential COPD treatments and has
therefore been used to assess the effects of anti-
inflammatory drugs on neutrophilic lung inflammation prior
to performing larger studies in COPD patients [16, 17]. LPS
inhalation in healthy subjects causes p38 MAPK activation in
bronchial epithelial cells [18]; these cells release chemokines
such as CXCL8 that promote neutrophil chemotaxis [19]. The
neutrophil chemotaxis observed after LPS inhalation in
healthy subjects should therefore be attenuated by drugs that
inhibit p38 MAPK activation; this hypothesis has not been
tested in human studies.
We have explored the effects of single doses of an orally
administered and inhaled p38 MAPK inhibitor (PH-797804
and PF-03715455, respectively) on neutrophilic lung inflam-
mation caused by LPS inhalation in healthy subjects. We also
investigated the effects of a single dose of an ICS (fluticasone
propionate) in this model. We present three separate clinical
trials, in healthy volunteers, using inhaled LPS challenges that
provide mechanistic insights into the effectiveness of oral and
inhaled p38 MAPK inhibitors in a human model of neutro-




Males and females of non-childbearing potential aged be-
tween 18 and 50 years were recruited. Subjects were lifelong
non-smokers, or ex-smokers for >1 year with <5 pack year
history. Subjects were required to have normal lung function,
normal bronchial reactivity to histamine (defined as a fall in
FEV1<20% after inhalation of histamine at concentrations up
to and including 16 mg/mL) and be able to produce an ade-
quate sputum sample at screening with a total cell count <14×
106 cells/g comprising <70 % neutrophils and <3 % eosino-
phils. These sputum cell criteria were used to exclude subjects
with excessive airway inflammation, which could be due to
acute infection or underlying pulmonary disease. Exclusion
criteria included an upper respiratory tract infection in the
previous 4 weeks, or any other infection within 1 week of
dosing, the presence of significant other medical conditions
or clinically significant abnormalities in biochemistry or
haematology blood results at screening. All subjects provided
written informed consent, and the studies were approved by
the local ethics committee. The studies are registered on
clinicaltrials.gov: NCT02084485, NCT01314885 and
NCT01364519.
Study design
Three randomised, double-blind, placebo-controlled cross-
over studies were performed; the effects of a single dose of
active treatment was investigated in all three studies. Study 1
was a two-way crossover study conducted at a single centre
(Kings College, London) where the active treatment was PH-
797804 30 mg administered orally. Studies 2 and 3 were con-
ducted at two UK centres: Quintiles Drug Research Unit,
London, and Medicines Evaluation Unit, Manchester. Study
2 was a three-way crossover study where the active treatments
were a single dose of PH-797804 30 mg administered orally
and a single dose of PF-03715455 20 mg by inhalation of
powder inside a capsule using a single-pin monodose inhaler
device (MIAT). Study 3 was a two-way crossover study where
the active treatment was a single dose of inhaled fluticasone
propionate 500 μg using the accuhaler™ device. The studies
were performed during the following time periods: study 1,
Sep 2006–Mar 2008; study 2, Jan 2011–Dec 2011; and study
3, Jul 2011–Jan 2012.
Subjects were assigned to a treatment sequence using
randomised blocks by means of a computer-generated pseu-
do-random code generated by Pfizer. A randomisation sched-
ule was provided to the investigator and in accordance with
the randomisation numbers; the subject received the study
treatment regimen assigned to the corresponding
randomisation number.
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The design of all three studies was similar. A baseline spu-
tum sample was obtained within 14 days of the first study
period when subjects were administered a single dose of
randomised treatment. LPS challenge was administered 24 h
after dosing with PH-797804/placebo in study 1; in study 2,
inhaled LPS was administered on day 2 which was either 24 h
after dosing with PH-797804 or 30 min after PF-03715455 as
a result of the double-dummy design; in study 3, inhaled LPS
was administered 30 min after dosing with fluticasone/place-
bo. Previous phase 1 studies in healthy subjects (unpublished)
showed that the time of maximum systemic concentration (t-
max) for PH-797804 and PF-03715455 were at approximately
24 h and 30 min, respectively, and therefore, the LPS chal-
lenges were planned to be performed at these times. Induced
sputum was obtained 6 h later to coincide with the maximal
inflammatory response caused by inhaled LPS. A washout
period of at least 21 days followed, with subjects returning
after 14 days of the washout period for induced sputum sam-
pling; this was performed to ensure that the total cell count,
total neutrophil count and total macrophage count were within
the range of −80 to +100 % of the screening values. This
criterion was used to ensure that sputum cell counts after
LPS challenge had returned to close to the original baseline
values; this was done to reduce data variability between treat-
ment periods. If these criteria were not met, then up to two
repeat visits to obtain sputum were allowed, with at least
4 days between sputum inductions. The next randomised
treatment day was scheduled at least 4 days after sputum in-
duction and was identical to the first treatment day. The inter-
val of 4 days between sputum inductions allowed any pro-
inflammatory effect caused by sputum induction to settle be-
fore the next attempt at sampling.
Safety was assessed in these studies by physical examina-
tions, haematology and biochemistry measurements, ECG
analysis and reporting of any adverse events.
LPS challenge
For each challenge, a 1-mg vial of lyophilised LPS
(Escherichia coli serotype O26:B6, ref. L-2654, Sigma-
Aldrich, Dorset, UK) was diluted with 4 mL of 0.9 % w/v
sodium chloride. The reconstitution produced a 0.25 mg/mL
solution, of which 2 mL was placed into the pre-calibrated
dosimeter pot and administered via five inhalations from a
breath-activated dosimeter (Mefar dosimeter MB3, Brescia,
Italy). Each inhalation was performed over 3 s with a 6-s
breath hold. The dosimeter delivered 12 μL for each inhala-
tion which resulted in a total dose of 15 μg LPS.
Induced sputum
Sputum was induced using normal saline after inhalation of
salbutamol, and processing was performed using dithiothreitol
(DTT) as previously described [20]. The supernatants were
stored at −80 °C for later analysis, while cells were used to
produce cytoslides (Cytospin 4, Shandon, Runcorn, UK) for
differential cell counting and immunocytochemistry.
Cytoslides for differential cell count were fixed in methanol
(Sigma) and then stained with Rapi-Diff® (GCC Diagnostics,
Sandyhurst, UK) or Wright-modified Giemsa (Accustatin
WG-18, Sigma-Aldrich); a minimum of 400 non-squamous
cells were counted and differential cell counts obtained as
percentage of total non-squamous cells. Cell viability was
analysed by trypan blue exclusion. Cytoslides with % squa-
mous cell counts <20 % were deemed to be of acceptable
quality for differential cell counting. Unfixed cytoslides were
wrapped in aluminium foil and stored frozen at −80 °C for
immunocytochemistry.
Sputum supernatant and plasma protein biomarkers
In studies 1 and 2, sputum supernatants were analysed for
interleukin 6 (IL-6), myeloperoxidase (MPO), monocyte che-
motactic protein-1 (MCP-1) and macrophage inflammatory
protein-1β (MIP-1 β), using electrochemiluminescent immu-
noassays (ECLIA) or enzyme-linked immunosorbent assays
(ELISA); the manufacturers are listed in the online supple-
ment. In study 3, sputum supernatants were analysed for IL-
6, MCP-1 and MIP-1β by the same method.
Blood samples were obtained in studies 2 and 3 to obtain
plasma measurements of IL-6, MCP-1, MIP1β, CC16, fibrin-
ogen and CRP levels; pre-dose and 6 h post-LPS samples
were used for statistical analysis. This coincided with the tim-
ings of sputum measurements of inflammation biomarkers.
Immunocytochemistry
Frozen cytospins created from sputum cells were analysed for
phosphorylated-Heat Shock Protein 27 (phospho-HSP27) and
phospho-p38 expression in sputum macrophages. The
methods are fully described in the online supplement.
Phospho-p38 and phospho-HSP27 immunoreactivity is pre-
sented as percentage of the macrophage population. All anal-
yses were carried out by blinded observers.
Pharmacokinetics
Blood samples were collected at 0 h and around the time of
tmax and at the time of sputum induction (23 and 30.5 h post
dose for PH-797804 and 1.5 h and 6.5 h post-dose for PF-
03715455) to provide plasma for pharmacokinetic analysis
using previously validated analytical methods. Sparse sam-
pling was employed to provide data at Cmax to confirm drug
levels of PH-797804, PF-03715455 and fluticasone propio-
nate relative to LPS challenge. PF-03715455, PH-797804
and fluticasone propionate plasma concentrations were
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analysed using high-performance liquid chromatography tan-
dem mass spectrometric methods at Advion BioServices, Inc.
(Ithaca, NY, USA), PPD (Richmond, VA, USA) and York
Bioanalytical Solutions (York, UK), respectively; the lower
limits of quantification were 10 pg/mL, 0.1 ng/mL and 3 pg/
mL, respectively.
Statistical methods
Sputum neutrophil percentage was the primary endpoint for all
three studies. The neutrophil percentage was modelled using a
mixed effects analysis of covariance (ANCOVA) model appro-
priate for a two-period, two-treatment or three-period, three-
treatment crossover design. The fixed effects in the model were
treatment and period. Subjects were modelled as a random
effect. Additionally, the period-specific baseline was modelled
as a covariate. This model was used for all sputum inflamma-
tory markers, including the immunohistocytochemistry, where
cell counts were log transformed before analyzing the data and
percent differentials were not transformed. This model used all
available information from the subject visits to estimate treat-
ment effects; the data for subjects whowere randomised but did
not complete the study were still included in the modelling.
Ninety percent confidence intervals of the difference (non-
transformed data) or the ratio (log-transformed data) were con-
structed based on the ANCOVA model.
An additional non-informative Bayesian analysis was pro-
posed for studies 2 and 3, but only the frequentist analysis is
presented here. Bayesian analyses offer the advantage of eas-
ily combining results across multiple studies. A Bayesian
analysis was proposed to aggregate data across these three
studies in a more coherent framework. The frequentist analy-
sis was pre-specified and is presented in this paper to limit
conclusions to only the data in a single study. The non-
informative Bayesian analysis and the frequentist analysis
gave similar results and showed no difference in interpretation
or conclusion, as expected based on the statistical theory be-
hind these analyses.
Systemic biomarkers were analysed using a similar mixed
effects model; these models also adjusted for pre-dose base-
line values, which were obtained 24 h prior to LPS challenge
in study 2 and 30 min prior to LPS challenge in study 3.
The three studies have all been powered at least at 80 %
with an alpha of 0.05 (study 1 and 2) or 0.10 (study 3). The
sample size calculations for study 1 were based on previous
LPS challenge data in healthy volunteers. A maximum sam-
ple size of 24 was estimated to be sufficient based on the
standard deviation observed previously for measurements in-
cluding sputum neutrophil percentage, and an interim analy-
sis after 12 subjects was planned to re-evaluate variability
within the study and re-estimate the sample size. Study 1
was stopped at the interim analysis, as the variability ob-
served for neutrophil percentage was lower than anticipated.
Study 1 was used to estimate the within subject variability
(SD) for study 2; standard deviation for sputum neutrophil
percentage of 19 % and an effect size of 15 % was assumed,
giving a sample size of 18. The variability from study 2 was
used to further refine the estimate of within-subject variability
for study 3, SD=15, with an assumed effect size of 15 %
which gave a sample size of 12.
Results
The number of subjects randomised and who completed the
studies is shown in Fig. 1. The majority of screen failures were
due to failure to provide an adequate sputum sample accord-
ing to the inclusion criteria. The next most common reason
73 screened
22 randomised
















Fig. 1 Flow diagram of patient numbers. This shows the number of
subjects screened, randomised, withdrawn and completed for each study
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was the discovery of significant medical conditions or abnor-
mal blood results at screening. The demographic details of the
subjects randomised are shown in the online supplement. In
study 1, 22 male subjects were randomised (mean age
34 years), of which 13 completed both treatment periods. In
study 2, 39 male subjects were randomised (mean age
28 years), of which 14 completed all three treatment periods.
In study 3, 17 male subjects were randomised (mean age
28 years), of which 14 completed both treatment periods.
The major reason for non-completion in all three studies was
failure to meet the sputum reproducibility criteria before en-
tering the next treatment period. PH-797804 and PF-
03715455 were safe and generally well tolerated; a summary
of the number of subjects experiencing adverse events by
MedDRA System Organ Class is shown in the online supple-
ment. Two subjects suffered with AEs requiring withdrawal in
study 2; one reported malaise after placebo treatment, and one
developed cellulitis 5 days after being treated with PF-
03715455; further details of this event are in the online
supplement.
Sputum neutrophil percentage
Table 1 displays the mean sputum neutrophil percentage in all
three studies at baseline and 6 h following LPS challenge. The
baseline neutrophil percentages were similar across the three
studies. Similar values were observed within each study prior
to each treatment period (approximately 41–44 %), demon-
strating no carry-over effect of LPS challenge on neutrophil
counts. There were similar increases in mean sputum neutro-
phil percentage in the placebo period after LPS challenge
(which will be referred to as the LPS response from now)
across the three studies; modelled LPS responses of approxi-
mately 30 % were observed.
There was a statistically significant inhibition of the
sputum neutrophil percentage post-LPS challenge caused
by PH-797804 compared to placebo in studies 1 and 2
(p=0.0096 and 0.0001, respectively), with 15.1 and
15.3 % reduction in mean sputum neutrophil percentage
(Fig. 2), representing approximately 50 % attenuation of
the modelled LPS response. Study 2 also showed signifi-
cant inhibition of sputum neutrophil percentage post LPS
challenge after administration of PF-03715455 of 8.0 %
which was approximately 25 % attenuation of the
modelled LPS response (p=0.031). Sputum neutrophil
percentage post-LPS challenge was not changed signifi-
cantly by fluticasone propionate (p=0.55).
Secondary endpoint sputum measurements
The total neutrophil cell count was increased by LPS chal-
lenge in the placebo treatment period in all three studies
(data shown in online supplement). PH-797804 signifi-
cantly inhibited the total neutrophil count in sputum com-
pared to placebo in studies 1 and 2. PF-03715455 and
fluticasone propionate had no effects on neutrophil
counts. In study 2, both PH-797804 and PF-03715455
significantly attenuated the reduction in sputum macro-
phage percentage compared to placebo; this is compatible
with the inhibitory effect of these drugs on the increase in
sputum neutrophil percentage after LPS challenge (data
shown in online supplement).
Sputum supernatant cytokine levels were generally in-
creased by LPS challenge in the placebo treatment period in
all three studies (data shown in online supplement). In study 1,
PH-797804 did not significantly inhibit cytokine levels com-
pared to placebo, but there was evidence of trends towards
significance for MCP-1 and MPO (see Fig. 3). In study 2,
PH-797804 significantly reduced IL-6, MPO, MCP-1 and
MIP-1β levels compared to placebo. PF-03715455 and
fluticasone propionate had no effects on sputum cytokine
measurements.
Systemic biomarkers
PH-797804 caused statistically significant reductions in IL-6,
MIP1β, MCP-1, CC16 and CRP levels compared to placebo
at 6 h post-LPS challenge (see Fig. 4 for ratio of means;
numerical values at each time point are shown in online
supplement). When comparing PF-03715455 to placebo, sta-
tistically significant reductions in IL-6, MCP-1, MIP1β and
CC16 were observed. PH-797804 showed a greater numerical
effect on these biomarkers than PF-03715455. Fluticasone
propionate had no effect on this set of systemic biomarkers
compared to placebo.
Table 1 Mean sputum neutrophil percentage at baseline and 6 h post-
LPS challenge
Study Treatment Period Number Mean (SD)
1 Placebo Baseline 18 44.1 (17.0)
6 h post-LPS 17 74.0 (17.6)
PH-797804 30 mg Baseline 17 42.1 (17.8)
6 h post-LPS 14 56.4 (24.0)
2 Placebo Baseline 27 41.5 (17.6)
6 h post-LPS 25 76.2 (12.1)
PF-03715455 20 mg Baseline 25 44.9 (15.6)
6 h post-LPS 24 66.4 (14.0)
PH-797804 30 mg Baseline 22 42.0 (13.4)
6 h post-LPS 22 60.4 (17.9)
3 Placebo Baseline 14 41.6 (12.1)
6 h post-LPS 11 74.1 (12.2)
Fluticasone 500 μg Baseline 15 43.2 (15.2)
6 h post-LPS 15 70.0 (12.9)
SD standard deviation
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Sputum immunohistochemistry
Immunohistochemistry performed on samples in study 2
showed that phospho-P38 and phospho-HSP27 expression
in sputum cells was restricted to macrophages, with little or
no expression in neutrophils; we have previously reported this
finding in healthy subjects and COPD patients [6]. LPS chal-
lenge did not increase the percentage of macrophages express-
ing phospho-P38 or phospho-HSP27 compared to baseline in
the placebo treatment period (see Table 2). PH-797804 had no
effect on the percentage of macrophages expressing phospho-
P38 and a non-significant difference on phospho-HSP27 after
LPS challenge. In contrast, PF-03715455 significantly re-
duced the percentage of macrophages expressing phospho-
P38 and phospho-HSP27; these decreases correspond to an
attenuation of the baseline measurements of approximately
45–50 %.
Pharmacokinetics
The systemic drug concentrations at the expected Cmax, for
each study, are shown in Table 3. As expected, the plasma
Cmax for orally administered PH-797804 was greater than
the inhaled drugs. Sputum supernatants, from study 2, were
also analysed for drug concentrations, for the ten subjects that
had received all three treatments; the geometric mean sputum
concentration of PF-03715455 after receiving an inhaled dose
was 20 nM (range 4–73 nM), while the geometric mean spu-
tum concentration of PH-797804 after receiving an oral dose
was 4 nM (range 2–7 nM).
Fig. 2 Inhibition of LPS induced
sputum neutrophil percentage.
The reduction in sputum
neutrophil percentage caused by
active treatments compared to
placebo are shown; bars are mean
difference and error bars are 90 %
CI (*p<0.05 and **p<0.01 from
ANCOVA model)
Fig. 3 Sputum cytokine data.
The ratio of means (with bars
showing 90 % CI) of active
treatment compared to placebo is
shown.Numbers in brackets on x-
axis denote study number, i.e.,
study 1, 2 or 3. Drug
abbreviations are as follows:
804=797804, 445=03715445,
FP fluticasone propionate
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Discussion
The p38MAPK inhibitors PH-797804 and PF-03715455 both
reduced neutrophilic airway inflammation after LPS challenge
in healthy subjects. A consistent effect of PH-797804 on spu-
tum neutrophils was observed in two different studies. In con-
trast, inhaled fluticasone propionate at a dose of 500μg had no
effect. Interestingly, the orally administered p38MAPK inhib-
itor had a greater effect on sputum neutrophils and supernatant
cytokines than the inhaled drug. Inhaled delivery is often
favoured for respiratory drugs, as it increases lung compared
to systemic exposure with the aim of increasing therapeutic
pulmonary effects relative to systemic side effects. However,
it appears that increased systemic exposure of orally adminis-
tered PH-797804 provided superior pulmonary anti-
inflammatory effects in a human inhaled LPS challenge model
that is poorly responsive to corticosteroids.
PH-797804 and PF-03715455 both suppressed pulmonary
and systemic biomarkers of inflammation, with greater effects
observed for PH-797804. PH-797804 had a significant effect
on sputum neutrophils in study 1. Study 2 confirmed a similar
effect size, indicating that PH-797804 had a repeatable effect
on the reduction of neutrophilic airway inflammation. Study 2
showed that PH-797804 significantly inhibited sputum cyto-
kines, while only trends to significance were observed in
study 1; the differences between studies are likely to be due
to variability in relatively limited sample sizes.
The effects of PH-797804 and PF-03715455 on systemic
inflammation could either be attributed to the activity of the
compound absorbed into the systemic circulation, or to the
inhibition of pulmonary inflammation leading to a reduced
systemic response to inhaled LPS. The plasma concentrations
of PF-03715455 at the time of LPS challenge were below the
IC50 value for the drug (enzyme IC50 5–50 pM), suggesting
Fig. 4 Systemic biomarker data.
The ratio of means (with bars
showing 90 % CI) of active
treatment compared to placebo is
shown.Numbers in brackets on x-
axis denote study number, i.e.,
study 2 or 3. Drug abbreviations
are as follows: 804=797804,
445=03715445, FP fluticasone
propionate
Table 2 Inhibition of phospho-
p38 and phospho-HSP27 expres-
sion in sputum samples in study 2
Comparison vs placebo
Baseline Post-LPS Mean % inhibition P value Confidence limits
Phospho-p38 expression
PF-03715455 51.30 % 25.03 % −14.59 0.0022 −21.85; −7.34
PH-797804 40.76 % 38.00 % −1.67 0.6958 −8.89; 5.55
Placebo 39.01 % 37.97 % NA NA NA
Phospho-HSP27 expression
PF-03715455 47.88 % 26.89 % −24.01 0.0014 −35.53; −12.49
PH-797804 49.34 % 42.27 % −5.81 0.4060 −17.53; 5.90
Placebo 47.16 % 46.36 % NA NA NA
Samples post-LPS challeng were analysed. The mean percentage of macrophages expressing the protein is
shown, with mean inhibition and 90 % confidence intervals
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minimal systemic activity. In our view, the anti-inflammatory
effects of PF-03715455 on systemic biomarkers were mainly
due to the effects of the compound in the lung. In contrast, the
increased effects of PH-797804 compared to PF-03715455 in
this LPS challenge model are probably due to greater systemic
exposure of the oral compound limiting inflammatory cell
recruitment into the lungs and also reducing systemic
inflammation.
The greater effect of PF-03715455 on sputum biomarkers
of p38 MAPK activation may be explained by the fact that the
geometric mean sputum concentration of PF-03715455 was
20 nM, which is above the enzyme IC50 for PF-03715455 (5–
50 pM). The geometric mean concentration of PH-797804 in
sputum supernatant was 4 nM, which is similar to the IC50 for
PH-797804 (3 nM).
A bronchoscopy study has shown that inhaled LPS chal-
lenge in healthy subjects activates p38 MAPK in bronchial
epithelial cells [18]. These cells release neutrophil
chemoattractants such as CXCL8 after p38 MAPK activation
[6, 21]. Epithelial cells may be key controllers of the inflam-
matory response to LPS in the airways. Both PH-797804 and
PF-03715455 significantly inhibit IL-8 production from epi-
thelial cells [Pfizer, data on file] and may therefore reduce
neutrophil recruitment to the lung. Cytokines measured in
induced sputum are secreted either by cells within the airway
lumen or by airway epithelial cells. The lack of effect of PF-
03715455 on sputum supernatant cytokines, in contrast to PF-
03715455 inhibition of sputum macrophage p38 MAPK acti-
vation, suggests that the cytokines measurable in induced spu-
tum were predominantly derived from epithelial secretion.
We observed no upregulation of phospho-p38 or phospho-
HSP27 expression at 6 h after LPS challenge. This was per-
haps surprising, as LPS challenge increases bronchial epithe-
lial p38 MAPK activation [18], and LPS stimulation is known
to upregulate phospho-P38 expression in human alveolar
macrophages [9]. However, the phospho-p38 expression in
LPS-stimulated alveolar macrophages is transient [9], and it
is possible that the 6 h sampling point after LPS challenge was
not optimal for this measurement. Nevertheless, measuring
p38 MAPK activation in sputum samples provided insights
into the relative effects of the drugs studied on cells that are
resident within the airway lumen.
It has been shown that PH-797804 improves FEV1 by
93 mL in COPD patients treated for 6 weeks [12]. The current
study shows that PH-797804 is capable of reducing airway
neutrophil numbers and airway inflammatory biomarkers in
healthy subjects after LPS challenge, providing an insight into
the possible mechanisms by which this compound exerts anti-
inflammatory effects in the airways. The oral p38 MAPK
inhibitor losmapimod failed to reduce sputum neutrophil
counts in COPD patients after 12-week treatment [11]; the
investigators suggested that this may be due to a technical
failure of the study regarding sputum analysis. We studied
PH-797804 in young healthy volunteers, as it is safer to con-
duct LPS challenges in these subjects compared to older indi-
viduals or even patients with COPD [22]. The reduction in
airway neutrophil numbers in this healthy volunteer challenge
model differs from studying drug effects in COPD patients
with chronic neutrophilic airway inflammation; nevertheless,
our results support the case for further studies to investigate
the effects of this drug on sputum neutrophil numbers in
COPD patients.
It has been reported that 6-day treatment with the oral cor-
ticosteroid prednisolone had no effect on airway inflammation
in an LPS challenge study but suppressed plasma CRP levels
[16]. The lack of effect of inhaled fluticasone propionate on
airway inflammation is consistent with these previous find-
ings. Given the lack of effect of oral prednisolone on airway
inflammation in this model, we speculate that a higher dose of
inhaled fluticasone propionate, or given for a longer duration,
also would not have inhibited airway inflammation in this
acute model of lung neutrophilia, but this remains to be stud-
ied. It has been reported that a single dose of inhaled
fluticasone propionate can significantly inhibit the effects of
bronchial challenges in asthma [23]; notably, a single dose
given 30 min before allergen challenge had a similar effect
compared to 2 weeks prior treatment [24]. This supports the
use of a single dose of fluticasone propionate in challenge
models.
We started the LPS challenges at the time of maximum
plasma concentration of the drugs. As sputum samples were
taken at 6 h later, this gave the drugs a time window after
maximal plasma concentration to exert anti-inflammatory ef-
fects. Different factors will influence the effects of a single
Table 3 Plasma pharmacokinetics
Study Treatment Number Units 1.5 h 6.5 h 23 h 30.5 h
1 PH-797804 (30 mg) 17 ng/mL – – 38.9 (7.4) 37.8 (8.0)
2 PF-03715455 (20 mg) 26 pg/mL 472.6 (116.4) 110.6 (29.7) – –
PH-797804 (30 mg) 23 ng/mL – – 56.8 (18.7) 49.2 (14.7)
3 Fluticasone (500 μg) 15 pg/mL 56.0 (29.4) 37.31 (15.1) – –
The selected time points used in each study are shown
B–^ no samples were taken
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drug dose in the lungs, such as potency, plasma half-life
(which will influence total systemic exposure) and lung reten-
tion. This study attempted to capture the maximum effects of
the drugs based on the known maximal plasma concentration,
which were achieved at very different times (longer for PH-
797804, with an estimated tmax at approximately 23 h).
However, the effects of these drugs are dependent on many
factors, including the timing of the LPS challenge and the
number of drug doses administered before challenge.
Studies 1 and 3 (two-way crossover studies) had a com-
bined completion rate of 69% (27 out of 39 subjects), while in
study 2 (three-way crossover), the completion was 36 % (14
out of 39 subjects). This indicates a failure to meet the sputum
criteria of approximately 30 % occurs before each crossover
period. We set sputum criteria to limit the variability of the
primary endpoint; the practical drawback was the subsequent
drop-out rate. The data from patients who did not complete the
study were included in the statistical analysis, thus limiting the
bias potentially caused by only evaluating patients who com-
pleted the study. However, more data were available for pa-
tients who completed the study, and the effect sizes reported
here are applicable to healthy volunteers who met the sputum
criteria specified; these drug effects may vary with the sputum
criteria used.
The effects of PH797804 in studies 1 and 2 were very
similar. This indicates a reasonable degree of comparabil-
ity between the studies that used similar designs, and the
same inclusion criteria to recruit a homogenous volunteer
group (healthy males). Furthermore, many of our key find-
ings come from study 2, where both p38 MAPK inhibitors
were compared to placebo. Ideally, one would like to study
the three active treatments reported here within the same
crossover design; this would be a four-way crossover in-
cluding a placebo. However, the practical difficulties in
terms of subject drop outs that we experienced during a
three-way crossover would make a longer study extremely
difficult to complete.
P38 MAPK inhibitors have been in clinical development
for many years for a range of inflammatory diseases.
Unfortunately, many orally administered P38 MAPK inhibi-
tors have been poorly tolerated due to side effects. The devel-
opment of inhaled therapies may optimise the therapeutic in-
dex by increased pulmonary versus systemic exposure. We
have used a model of acute neutrophilic airway inflammation
to compare the effects of an oral and inhaled p38 MAPK
inhibitor, as well as an inhaled corticosteroid. The LPS chal-
lenge model mimics some aspects of acute exacerbations of
COPD, which are often caused by bacterial infections leading
to increased TLR signalling. PH-797804 and PF-03715455
both reduced airway and systemic inflammation after LPS
inhalation, and therefore show promise as potential new
anti-inflammatory treatments of neutrophilic airways diseases
such as COPD.
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